IRVINE, Calif., Sept. 15 /PRNewswire/ -- Masimo (Nasdaq: MASI) announced today the Japanese Ministry of Health, Labor and Welfare (MHLW) regulatory clearance of its noninvasive and continuous hemoglobin (SpHb) measurement, available as part of the Masimo rainbow SET® platform. Representing a breakthrough solution for noninvasively and continuously measuring a patient's hemoglobin level in real-time, SpHb tracks and trends hemoglobin levels without needles, time-consuming laboratory analysis, and risk of contamination associated with traditional blood tests.
The availability of noninvasive, continuous, and immediate hemoglobin measurements is expected to have wide-ranging clinical impact in Japan—from surgery and intensive care units to less acute care settings, including the emergency department and physician offices. SpHb may help clinicians determine whether a patient has a low hemoglobin level (known as anemia) and facilitate prompt detection of internal bleeding and more appropriate administration of blood transfusions—by referring to the SpHb measurement that is continuously displayed on Masimo rainbow SET Pulse CO-Oximeters™.
Now, clinicians in Japan can benefit from the full range of
physiologic measurements available on the Masimo rainbow SET
platform—including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®),
Pleth Variability Index
(PVI®), and acoustic respiration
rate (RRa™), in addition to the 'gold-standard'